GleamWall
中文EN

SCYX SCYNEXIS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1178253 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY544.0%
TTM net income YoY60.1%
TTM EPS YoY127.8%
Revenue 3-yr CAGR-48.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-126.9%
Net margin-53.5%
FCF margin—
EBITDA margin—

Returns

ROE-21.2%
ROA-17.0%
ROIC (approx.)-52.4%
Asset turnover0.32x

Leverage & solvency

Liabilities / assets13.1%
Debt / equity0.00x
Current ratio7.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.19x
Accruals ratio3.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$20.60M$3.75M
R&D expense$22.28M$26.41M
SG&A expense$14.39M$14.46M
Operating income-$16.07M-$37.12M
Interest expense$173,000$828,000
Pretax income-$8.61M-$21.14M
Income tax$0$151,000
Net income-$8.61M-$21.29M
EBITDA—-$37.12M
EPS (basic)-0.17-0.44
EPS (diluted)-0.17-0.44
Weighted avg. shares (diluted)49.93M48.51M
Balance sheet
Cash & equivalents$21.26M$16.59M
Short-term investments$18.77M$43.25M
Current assets$40.37M$72.18M
Total assets$59.03M$90.64M
Current liabilities$5.73M$24.10M
Total liabilities$9.65M$35.57M
Shareholders' equity$49.38M$55.08M
Shares outstanding5.44M37.97M
Cash flow statement
Operating cash flow-$5.28M-$24.01M
Investing cash flow$24.31M$6.15M
Financing cash flow-$14.17M-$139,000
Depreciation & amortization—$0
Stock-based compensation$2.85M$3.35M

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.